The patient with pCR at the time of trial enrollment had a bulky primary mass with extensive skin ulceration which was refractory to anthracycline and achieved a complete response after L-NMMA therapy (Fig. 1B–D) and showed the highest intensity of iNOS expression at baseline (BL) (Fig. 1A, D, E). Here, NOS2 is linked to Skin ulcer.